{"id":"bexarotene-with-carboplatin-and-paclitaxel","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Neuropathy"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Hypertriglyceridemia (bexarotene-related)"}]},"_chembl":{"chemblId":"CHEMBL1351","moleculeType":"Small molecule","molecularWeight":"371.25"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Bexarotene activates retinoid X receptors (RXR) to promote differentiation and apoptosis of malignant cells while potentially enhancing immune surveillance. Carboplatin is a platinum-based alkylating agent that cross-links DNA, while paclitaxel is a taxane that stabilizes microtubules and prevents cell division. The combination leverages both direct cytotoxic chemotherapy and immune-modulating effects.","oneSentence":"This combination uses bexarotene (a retinoid X receptor agonist) to enhance immune response alongside carboplatin and paclitaxel chemotherapy agents that damage cancer cell DNA and disrupt microtubule function.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:04:09.968Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic non-small cell lung cancer (Phase 3)"}]},"trialDetails":[{"nctId":"NCT00153842","phase":"PHASE1, PHASE2","title":"A Study of Paclitaxel and Carboplatin in Combination With Bexarotene Oral Capsules in Patients With Advanced Lung Cancer","status":"TERMINATED","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2001-08","conditions":"Carcinoma, Non-small-cell Lung","enrollment":33},{"nctId":"NCT00050960","phase":"PHASE3","title":"Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2002-05","conditions":"Non-small Cell Lung Cancer","enrollment":612}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"bexarotene with carboplatin and paclitaxel","genericName":"bexarotene with carboplatin and paclitaxel","companyName":"Eisai Inc.","companyId":"eisai","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses bexarotene (a retinoid X receptor agonist) to enhance immune response alongside carboplatin and paclitaxel chemotherapy agents that damage cancer cell DNA and disrupt microtubule function. Used for Advanced or metastatic non-small cell lung cancer (Phase 3).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}